Lovastatin suppresses the aberrant tau phosphorylation from FTDP-17 mutation and okadaic acid-induction in rat primary neurons

Neuroscience
R LiT Ma

Abstract

Statins are a class of cholesterol-lowering drugs and have been suggested therapeutic use for neurodegenerative diseases including Alzheimer's disease (AD). Our recent studies revealed a neuronal protective effect of lovastatin (LOV) from N-methyl-d-aspartic acid (NMDA) excitotoxicity. The neuroprotective mechanism of statins, however, is far unknown. Here we demonstrated that LOV suppressed the aberrant tau phosphorylation both from frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17) mutation and okadaic acid (OA) induction in cultured rat primary neurons. The protective effect of LOV occurred at multiple pathological sites of tau protein, including Tyr181, Tyr231 Ser202/Tyr205, Tyr212/Ser214 and Ser396/Ser404. Further analysis revealed that the potential mechanism of the suppressive effect of LOV resulted from two aspects, activating OA-inhibited protein phosphatase 2A (PP2A) activity and attenuating OA-induced activity of tau kinases CDK5/P25 and CDK2/4, but not glycogen synthase kinase 3β (GSK3β). These findings give new insights into the molecular mechanism of LOV-mediated neuroprotective effect and provide experimental evidence for its therapeutic use in AD.

References

Sep 1, 1993·Journal of Neurochemistry·C X GongK Iqbal
Jan 1, 1997·Journal of Neuropathology and Experimental Neurology·J J PeiI Grundke-Iqbal
Jul 8, 1999·Proceedings of the National Academy of Sciences of the United States of America·S RaoK Keyomarsi
Feb 24, 2001·Journal of Neurochemistry·Q W FanM Michikawa
Aug 28, 2002·Biochemical Society Transactions·B Wolozin
Nov 3, 2005·The European Journal of Neuroscience·Fei LiuCheng-Xin Gong
Apr 28, 2006·Neuroreport·SeungYong YoonDongHou Kim
Jul 27, 2006·Acta Neurologica Scandinavica. Supplementum·B WolozinA McKee
Jul 25, 2007·The Journal of Biological Chemistry·Stephen M OstrowskiGary Landreth
Feb 20, 2009·Journal of Neuropathology and Experimental Neurology·Moran BoimelHanna Rosenmann
May 12, 2009·Progress in Neurobiology·Peter J van der MostUlrich L M Eisel
Apr 22, 2010·Experimental Neurology·Qing WangMidori A Yenari
Jan 22, 2011·The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry·Avik Roy, Kalipada Pahan
Sep 3, 2011·Journal of Neurochemistry·Rolf Postina

❮ Previous
Next ❯

Citations

Nov 10, 2017·FEBS Letters·Goce Taleski, Estelle Sontag
Feb 27, 2020·International Journal of Molecular Sciences·Yu-Chia KaoKuen-Jer Tsai
Jul 25, 2021·Behavioural Brain Research·RuoLan CaiZhiyou Cai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.